Pulmonary Eosinophilia - 20 Studies Found Completed : A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma : Eosinophilic Asthma : 2011-01-25 : Drug: Reslizumab Patients were Completed : A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma : Eosinophilic Asthma : 2010-12-29 : Drug: Reslizumab 3.0 mg/kg or Terminated : Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma : Eosinophilic Asthma : 2011-02-04 : Drug: Reslizumab Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 da Completed : A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma : Eosinophilic Asthma : 2011-01-28 : Drug: Reslizumab Patients were Completed : A Phase IIa Study of KHK4563 : Uncontrolled and Suspected Eosinophilic Asthma : 2011-08-07 : Drug: KHK4563 every 4 weeks fo Recruiting : Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma : Severe Eosinophilic Asthma : 2015-09-04 : Drug: OC000459 Drug: Placebo Completed : Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma : Eosinophilic Asthma : 2012-01-03 : Drug: Reslizumab Reslizumab ad Active, not recruiting : Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study : Asthma : 2015-08-31 : Drug: Mepolizumab 100 mg SC ev Recruiting : Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients : Asthma : 2015-09-17 : Biological: Mepolizumab 100mg Completed : Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control : Asthma : 2014-10-30 : Biological: Mepolizumab Humani Next >>>